Prof. Dr. Nicola Aceto

Prof. Dr. Nicola Aceto

Full Professor at the Department of Biology
Deputy head of Institute of Molecular Health Sciences

ETH Zürich

Professur für Molekulare Onkologie

HPL H 12

Otto-Stern-Weg 7

8093 Zürich

Switzerland

Additional information

Research area

More than 90% of cancer-related deaths are due to the development of a metastatic disease, corresponding to more than 7 million deaths each year worldwide. The Aceto lab is interested in understanding the fundamental molecular mechanisms that drive cancer and its metastatic progression, with a particular focus on the analysis of circulating tumor cells. In our studies, we use a combination of molecular biology, next-generation sequencing, computational biology, microfluidic and robotic technologies, patient samples, in vivo models, genetic engineering, CRISPR screens and drug screens to better understand the biology and vulnerabilities of aggressive cancers. We collaborate actively with a number of academic research groups, hospitals, and healthcare companies throughout the world. Together, we strive to identify novel metastasis-relevant therapeutic opportunities to fight against the metastatic spread of cancer.

Nicola Aceto is Full Professor of Molecular Oncology at the ETH Zurich. Prior to joining ETH, he has been Swiss National Science Foundation Assistant Professor of Oncology at the University of Basel. The Aceto lab contributed to key discoveries in the metastasis field, including investigations of the biology and vulnerabilities of circulating tumor cells and their clusters, some of which already translated into clinical trials for patients with metastatic breast cancer. Nicola completed his training at the Friedrich Miescher Institute (FMI) in Basel, Switzerland, at the Massachusetts General Hospital Cancer Center and Harvard Medical School, and at the Broad Institute of MIT and Harvard in Boston, USA. To date, Nicola received three ERC Grants (StG 2015, PoC 2018, CoG 2020) and numerous awards related to his work on circulating tumor cells, including the Swiss Science Prize Latsis for Groundbreaking Cancer Research, the EACR Translational Cancer Research Award, the Robert Wenner Award from the Swiss Cancer League and the Friedrich Miescher Award for Outstanding Achievements in Biochemistry. He is an inventor in several patent applications related to the diagnosis and treatment of cancer, advisor for several companies with an interest in liquid biopsy, and co-founder of an ETH Spinoff biotech company dedicated to the development of new cancer medicines.

Honours

Year Distinction
2023 Robert Wenner Award, Swiss Cancer League
2023 The Dr. Ernst Th. Jucker Prize for Research in Molecular Oncology, Zurich, Switzerland
2023 The Pezcoller Foundation-EACR Translational Cancer Research Award, European Association for Cancer Research and Pezcoller Foundation
2022 EACR Top 10 Cancer Research Publication (Diamantopoulou et al., Nature, 2022), European Association for Cancer Research
2021 EACR Top 10 Cancer Research Publication (Gkountela et al., Cell, 2019), European Association for Cancer Research
2021 ERC Consolidator Grant
2021 Swiss Science Prize Latsis, Swiss National Science Foundation, Bern, Switzerland
2020 Friedrich Miescher Award for Outstanding Achievements in Biochemistry
2019 ERC Proof-of-Concept Grant
2019 Faculty of Medicine Alumni Award for Excellent Scientific Achievements, University of Basel
2019 Prize for Scientific Research in the Fight Against Cancer, Vaduz, Liechtenstein
2016 ERC Starting Grant
2016 Honorable mention, AAAS Wachtel Cancer Research Award, USA
2016 Swiss National Science Foundation Professorship
2013 Advanced Postdoc Mobility Fellowship, Swiss National Science Foundation
2013 Long-Term Fellowship, Human Frontiers Science Program
2012 Bruno Speck Award, Basel Stem Cell Network (BSCN), Switzerland
2012 Ed Fischer Outstanding Thesis Award, Friedrich Miescher Institute, Switzerland
2012 Long-Term Fellowship, European Molecular Biology Organization (EMBO) (respectfully declined)
2012 Postdoctoral Fellowship, American-Italian Cancer Foundation, New York, USA (respectfully declined)

Course Catalogue

Autumn Semester 2024

Number Unit
551-1525-00L Cancer Progression: Mechanisms, Targets and Therapeutic Approaches
JavaScript has been disabled in your browser